This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ANN ARBOR, Mich.,
Oct. 5, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that
James S. Kuo, M.D., M.B.A., the Company's Chief Executive Officer and Chairman, will provide a brief update on its Alzheimer's program at the NYC Medtech Forum. Adeona will be one of four featured companies at the invitation-only event on Tuesday evening,
October 11, 2011, at the offices of
Kaye Scholer, LLP in
New York City.
"We are thrilled to invite Dr. Kuo back to the NYC Medtech Forum following his presentation on Adeona's CNS clinical development programs last December," said
John R. Lieberman, CPA, Managing Director at Perelson Weiner, LLP. "Our exclusive forum offers a unique platform for companies in the life science sector to share the potential of their clinical programs and product candidates with our select invited guests."
About NYC Medtech
NYC Medtech is a professional platform that assists many different collaborators in the life science, biotech, device and pharma industries have successful outcomes. This unique program not only brings together companies and investors but all people that are involved from reporters, scientists, academia, trade organizations, international partners, etc. The NYC Medtech program introduces invited participants with relevant timely introductions whether through the website, email or the personal touch at the NYC Medtech Forum. The NYC Medtech initiative was created and founded by
John R. Lieberman at Perelson Weiner, LLP, along with
Wendy Brown of Merrill Lynch and
Ted King of SaddleRock Advisors. For more information about NYC Medtech, please visit the website at
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available:
reaZin™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and
wellZin™, a homeopathic over-the-counter medicine for reducing the duration and symptoms of the common cold. Adeona also operates Adeona Clinical Laboratory, a wholly owned clinical reference laboratory that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at
SOURCE Adeona Pharmaceuticals, Inc.